Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.
FRISCO, Texas, June 24, 2022 /PRNewswire/ — Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in…